Cover Image

Health-related quality of life in patients with Spinocerebellar Ataxia: a validation study of the EQ-5D-3L

Although health-related quality of life (HRQoL) has developed into a crucial outcome parameter in clinical research, evidence of the EQ-5D-3L validation performance is lacking in patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6. The objective of this study is to assess the acceptabili...

Full description

Saved in:
Bibliographic Details
Main Authors: Buchholz, Maresa (Author) , Weber, Niklas (Author) , Rädke, Anika (Author) , Faber, Jennifer (Author) , Schmitz-Hübsch, Tanja (Author) , Jacobi, Heike (Author) , Xie, Feng (Author) , Klockgether, Thomas (Author) , Michalowsky, Bernhard (Author)
Format: Article (Journal)
Language:English
Published: 2024
In: The cerebellum
Year: 2024, Volume: 23, Pages: 1020-1030
ISSN:1473-4230
DOI:10.1007/s12311-023-01597-3
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s12311-023-01597-3
Get full text
Author Notes:Maresa Buchholz, Niklas Weber, Anika Rädke, Jennifer Faber, Tanja Schmitz-Hübsch, Heike Jacobi, Feng Xie, Thomas Klockgether, Bernhard Michalowsky, The EUROSCA study group, The ESMI study group
Description
Summary:Although health-related quality of life (HRQoL) has developed into a crucial outcome parameter in clinical research, evidence of the EQ-5D-3L validation performance is lacking in patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6. The objective of this study is to assess the acceptability, validity, reliability, and responsiveness of the EQ-5D-3L. For n = 842 predominantly European SCA patients of two longitudinal cohort studies, the EQ-5D-3L, PHQ-9 (Patient Health Questionnaire), and ataxia-specific clinical assessments (SARA: Scale for Assessment and Rating of Ataxia; ADL: activities of daily living as part of Friedreich’s Ataxia Rating Scale; INAS: Inventory of Non-Ataxia Signs) were assessed at baseline and multiple annual follow-ups. The EQ-5D-3L was evaluated regarding acceptability, distribution properties, convergent and known-groups validity, test-retest reliability, and effect size measures to analyze health changes. The non-item response was low (EQ-5D-3L index: 0.8%; EQ-VAS: 3.4%). Ceiling effects occurred in 9.9% (EQ-5D-3L) and 3.0% (EQ-VAS) with a mean EQ-5D-3L index of 0.65 ± 0.21. In total, convergent validity showed moderate to strong Spearman’s rho (rs > 0.3) coefficients comparing EQ-5D-3L and EQ-VAS with PHQ-9, SARA, ADL, and INAS. EQ-5D-3L could discriminate between groups of age, SARA, ADL, and INAS. Intra-class correlation coefficients (EQ-5D-3LICC: 0.95/EQ-VASICC: 0.88) and Kappa statistics (range 0.44 to 0.93 for EQ-5D-3L items) indicated tolerable reliability. EQ-5D-3L shows small (effect size < 0.3) to moderate (effect size 0.3-0.59) health changes regarding ataxia severity. The analysis confirms an acceptable, reliable, valid, and responsive recommended EQ-5D-3L in SCA patients, measuring the HRQoL adequately, besides well-established clinical instruments.
Item Description:Veröffentlicht: 15 September 2023
Online veröffentlicht: 15. September 2023
Gesehen am 07.12.2023
Physical Description:Online Resource
ISSN:1473-4230
DOI:10.1007/s12311-023-01597-3

Similar Items